Dongmei Wang1, Yue Pan2, Kaibin Huang3, Zhenzhou Lin4, Zuoshan Xie5, Guanghui Liu6, Yongming Wu7, Shengnan Wang8. 1. Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong, China. Electronic address: wangdm03@qq.com. 2. Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong, China. Electronic address: panya915@qq.com. 3. Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong, China. Electronic address: hkb@smu.edu.cn. 4. Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong, China. Electronic address: doct_lin@163.com. 5. Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong, China. Electronic address: 757149942@qq.com. 6. Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong, China. Electronic address: 418861545@qq.com. 7. Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong, China. Electronic address: 13711530187@139.com. 8. Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong, China. Electronic address: wsnpumc@smu.edu.cn.
Abstract
PURPOSE: To evaluate the meaning of immunostaining of rat hippocampus with respect to clinical manifestations, Status epilepticus(SE)severity, treatment, and prognosis of New-Onset Refractory Status Epilepticus(NORSE) patients. METHODS: Consecutive patients with cryptogenic NORSE admitted to the neuro-intensive care unit (NICU) between January 2015 and October 2018 were screened, and those who had serum and cerebrospinal fluid (CSF) immunostaining were included. Subsequently, the patients were classified into positive and negative immunostain groups. Immunotherapy was initiated in patients who progressed to super-RSE (SRSE). The demographic, and clinical, and immunostaining data were collected. The prognosis was evaluated by modified Rankin scale (mRS) at discharge (short-term prognosis) and 6 months (long-term prognosis), with mRS score ≤2 defined as the favorable outcome. The clinical manifestations, treatment response, and prognosis were compared between the patients with positive and negative immunostains. RESULTS: 4/18 patients had positive immunostaining on both CSF and serum, 8 (had positive immunostaining on serum only, while 6 had negative immunostaining on serum and CSF. Twelve (66.7 %) patients progressed to SRSE, with no difference between the positive and negative immunostaining groups (P = 1.000). 7/18 patients had a favorable outcome at discharge and 11/18 after 6 months. No significant difference on the prognosis was detected between patients with positive and negative serum/CSF immunostaining and between the patients with or without immunotherapy at discharge or 6-month follow-up (P = 0.657/P = 0.502, P = 0.445/P = 0.829, P = 0.622, P = 0.567, respectively). CONCLUSIONS: The immunostaining on serum and/or CSF from NORSE patients did not indicate the progression to SRSE and clinical outcomes.
PURPOSE: To evaluate the meaning of immunostaining of rat hippocampus with respect to clinical manifestations, Status epilepticus(SE)severity, treatment, and prognosis of New-Onset Refractory Status Epilepticus(NORSE) patients. METHODS: Consecutive patients with cryptogenic NORSE admitted to the neuro-intensive care unit (NICU) between January 2015 and October 2018 were screened, and those who had serum and cerebrospinal fluid (CSF) immunostaining were included. Subsequently, the patients were classified into positive and negative immunostain groups. Immunotherapy was initiated in patients who progressed to super-RSE (SRSE). The demographic, and clinical, and immunostaining data were collected. The prognosis was evaluated by modified Rankin scale (mRS) at discharge (short-term prognosis) and 6 months (long-term prognosis), with mRS score ≤2 defined as the favorable outcome. The clinical manifestations, treatment response, and prognosis were compared between the patients with positive and negative immunostains. RESULTS: 4/18 patients had positive immunostaining on both CSF and serum, 8 (had positive immunostaining on serum only, while 6 had negative immunostaining on serum and CSF. Twelve (66.7 %) patients progressed to SRSE, with no difference between the positive and negative immunostaining groups (P = 1.000). 7/18 patients had a favorable outcome at discharge and 11/18 after 6 months. No significant difference on the prognosis was detected between patients with positive and negative serum/CSF immunostaining and between the patients with or without immunotherapy at discharge or 6-month follow-up (P = 0.657/P = 0.502, P = 0.445/P = 0.829, P = 0.622, P = 0.567, respectively). CONCLUSIONS: The immunostaining on serum and/or CSF from NORSE patients did not indicate the progression to SRSE and clinical outcomes.